Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Libido, menopause, and estrogen replacement therapy.

M K Beard1, L R Curtis

  • 1Clinical Faculty, University of Utah School of Medicine, Salt Lake City.

Postgraduate Medicine
|July 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Biomarker responses and disease susceptibility in juvenile rainbow trout Oncorhynchus mykiss fed a high molecular weight PAH mixture.

Environmental toxicology and chemistry·2011
Same author

Formation of nitro musk adducts of rainbow trout hemoglobin for potential use as biomarkers of exposure.

Aquatic toxicology (Amsterdam, Netherlands)·2004
Same author

Roles of uptake, biotransformation, and target site sensitivity in determining the differential toxicity of chlorpyrifos to second to fourth instar Chironomous riparius (Meigen).

Aquatic toxicology (Amsterdam, Netherlands)·2004
Same author

Vitamin and thyroid status in arctic grayling (Thymallus arcticus) exposed to doses of 3,3',4,4'-tetrachlorobiphenyl that induce the phase I enzyme system.

Chemosphere·2001
Same author

Organophosphate antagonism of the androgen receptor.

Toxicological sciences : an official journal of the Society of Toxicology·2001
Same author

Dieldrin induces cytosolic [3H]7, 12-dimethylbenz[a]anthracene binding but not multidrug resistance proteins in rainbow trout liver.

Journal of toxicology and environmental health. Part A·2000
Same journal

CV risk: if you aren't testing ACR, you aren't seeing the full picture.

Postgraduate medicine·2026
Same journal

Anti-TNF-induced vasculitis: analysis of data from the French national pharmacovigilance database.

Postgraduate medicine·2026
Same journal

Relationship of serum nesfatin-1 levels with body mass index and c-reactive protein in patients presenting to the emergency department with epileptic seizures.

Postgraduate medicine·2026
Same journal

Clinical pharmacokinetics of colistimethate sodium and formed colistin in patients with renal impairment or on dialysis modalities: a systematic review and implications for precision dosing.

Postgraduate medicine·2026
Same journal

The role of type D personality in pregnancy symptom severity, functional limitations, and maternal ambivalence.

Postgraduate medicine·2026
Same journal

Operational and demographic predictors of leaving without being seen in a high-volume tertiary emergency department: a five-year case-control study.

Postgraduate medicine·2026
See all related articles

Many women hesitate to discuss decreased sexual desire with doctors. This study suggests specific questioning and hormone replacement therapy for sexual dysfunction due to genitourinary atrophy or low estrogen.

Area of Science:

  • Reproductive Medicine
  • Women's Health
  • Endocrinology

Background:

  • Patient reluctance to discuss sexual concerns with physicians is common.
  • Sexual dysfunction can significantly impact quality of life.
  • Decreased libido may be linked to hormonal changes in women.

Purpose of the Study:

  • To highlight the importance of physician-initiated inquiry into sexual dysfunction.
  • To propose a treatment approach for specific types of female sexual dysfunction.
  • To address sexual dysfunction secondary to genitourinary atrophy and declining estrogen levels.

Main Methods:

  • Recommending specific patient questioning to identify sexual dysfunction symptoms.
  • Outlining a hormone replacement therapy (HRT) program.

Related Experiment Videos

  • Targeting HRT for women with genitourinary atrophy and loss of libido.

    • Main Results:

    • Physician-led questioning can effectively elicit patient concerns about sexual dysfunction.
    • Hormone replacement therapy is presented as a viable treatment option.
    • The study provides a framework for managing estrogen-related sexual dysfunction.

    Conclusions:

    • Proactive physician inquiry is crucial for addressing female sexual dysfunction.
    • Hormone replacement therapy offers a potential solution for specific patient groups.
    • Managing genitourinary atrophy and estrogen decline can improve sexual health in women.